Zimmer Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Zimmer Partners’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-330,834	Closed	-$4.95M	–	122
2025 Q3	$4.95M	Buy	330,834 +77,934	+31%	+$950K	0.11%	101
2025 Q2	$2.95M	Buy	+252,900	New	+$2.3M	0.06%	124
2020 Q1	–	Sell	-36,500	Closed	-$1.09M	–	78
2019 Q4	$1.09M	Hold	36,500	–	–	0.02%	72
2019 Q3	$1.13M	Hold	36,500	–	–	0.01%	92
2019 Q2	$1.76M	Buy	+36,500	New	+$1.62M	0.02%	91

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Zimmer Partners's ADPT Position: Q4 2025 in Review

Zimmer Partners sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 330,834 shares — an estimated $4.95M sold.

Zimmer Partners first reported a position in ADPT in Q2 2019 and held it in 5 quarters. The position peaked at $4.95M in Q3 2025. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Zimmer Partners reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Zimmer Partners sold 330,834 Adaptive Biotechnologies shares in Q4 2025, an estimated $4.95M.
Zimmer Partners first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 5 quarters.
Zimmer Partners's Adaptive Biotechnologies position peaked at $4.95M in Q3 2025.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Zimmer Partners's 13F filing for Q4 2025, filed 17 Feb 2026.